Actively Recruiting
International Observational Study on Anifrolumab Use in Systemic Lupus Erythematosus Across Multiple Countries
Led by AstraZeneca · Updated on 2026-09-01
200
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.
CONDITIONS
Brief Title
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here